slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 217,741-217,770
Pages 10,126
Rows per page 30
Component
217,741-217,770 of 303,780
30
Includes footnotes regarding exclusions for purchase accounting average balances.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
31
Flushing Financial | Results Presentation Deck | 37 slidesFlushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
32
Includes adjustments for credit losses, fair value adjustments, asset sales, and other non-recurring items.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
33
The table provides a detailed breakdown of adjustments for the years 2017-2022.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
34
The table includes adjustments for fair value hedges, purchase accounting, and tax equivalents.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
35
Data is in thousands of dollars.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
36
Flushing Financial | Results Presentation Deck | 37 slidesFlushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
02
Genelux | Investor Presentation Deck | 38 slidesGenelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
03
Genelux | Investor Presentation Deck | 38 slidesGenelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
05
The slide uses a Gantt-style visualization to map drug development progress against clinical phases.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Problem1 hit
06
Uses a process diagram to illustrate the transition from cold to hot tumor states.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Problem1 hit
07
The central diagram illustrates the biological mechanism of action, contrasting the absence vs. presence of effector T cells.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a timeline to establish market validation through historical M&A and financing events.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a list-based comparison and a logo-grid to frame the competitive landscape.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a pyramid diagram to represent the evolution of oncolytic virus technology, with Genelux's platform at the top.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
11
The slide uses a document-style container for patient background and icon-based lists for clinical outcomes.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
13
Data table presents ORR, Duration of Response, CA-125 response, PFS, and OS across patient subgroups.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
14
Includes a spider plot (tumor shrinkage over time) and a waterfall plot (duration of response).Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
Kaplan-Meier survival curve showing patient outcomes.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
17
The slide uses a cross-trial comparison to highlight the efficacy of Olvi-Vec in heavily pre-treated patients compared to other standard regimens.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
18
The slide outlines a randomized, open-label trial comparing Olvi-Vec + Platinum-doublet + Bevacizumab against a standard comparator arm.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
19
Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
20
Includes two specific patient case studies with longitudinal data and RECIST response metrics.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
21
Includes a bio for Benny Li, PhD, CEO of Newsoara.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
22
The table outlines a strategic partnership involving funding and regional commercialization rights.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
23
The slide highlights a combination therapy approach using two distinct technologies with separate clinical trial data.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
24
Includes a map of the US as a background element, likely to denote the geographic scope of the market sizing.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Market Size1 hit
25
The slide highlights physical assets and operational capacity.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Market Size1 hit
26
The slide uses a hub-and-spoke style layout to show the four pillars supporting the central launch strategy.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
27
The slide categorizes the platform's capabilities into therapeutic genes, immune modularity, and therapeutic antibodies.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit